NCT00305877View on ClinicalTrials.gov

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

February 29, 2012

Conditions
Stage IA Pancreatic CancerStage IB Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic Cancer
Interventions
BIOLOGICAL

cetuximab

Given IV

DRUG

gemcitabine hydrochloride

Given IV

DRUG

capecitabine

Given orally

RADIATION

radiation therapy

Undergo radiation therapy

BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00305877 - Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery | Biotech Hunter | Biotech Hunter